Bimatoprost Drug Pad-IOL System (BIM-IOL System) — Full data
Q4 2026
• BIM-IOL System: Four-year efficacy and safety follow-up expected in fourth quarter of 2026.Source filing
SGP biotech catalysts & pipeline
SPYGLASS PHARMA INC · Data as of 2026-09-08
Upcoming catalysts
Bimatoprost Drug Pad-IOL System (BIM-IOL System) — NDA/BLA submission
in 2028
We expect to complete enrollment in 2027 and, pending successful Phase 3 results, we plan to submit a 505(b)(2) New Drug Application (NDA) to the FDA in 2028.Source filing